WO2000055321A3 - Vertebrate protein slit, dna sequence encoding it and uses thereof - Google Patents

Vertebrate protein slit, dna sequence encoding it and uses thereof Download PDF

Info

Publication number
WO2000055321A3
WO2000055321A3 PCT/US2000/007040 US0007040W WO0055321A3 WO 2000055321 A3 WO2000055321 A3 WO 2000055321A3 US 0007040 W US0007040 W US 0007040W WO 0055321 A3 WO0055321 A3 WO 0055321A3
Authority
WO
WIPO (PCT)
Prior art keywords
slit
methods
given
protein
sequence encoding
Prior art date
Application number
PCT/US2000/007040
Other languages
French (fr)
Other versions
WO2000055321B1 (en
WO2000055321A2 (en
Inventor
Yi Rao
Jane Y Wu
Original Assignee
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington filed Critical Univ Washington
Priority to CA002365214A priority Critical patent/CA2365214A1/en
Priority to AU37551/00A priority patent/AU3755100A/en
Priority to EP00916449A priority patent/EP1163336A2/en
Priority to JP2000605739A priority patent/JP2002538823A/en
Publication of WO2000055321A2 publication Critical patent/WO2000055321A2/en
Publication of WO2000055321A3 publication Critical patent/WO2000055321A3/en
Publication of WO2000055321B1 publication Critical patent/WO2000055321B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)

Abstract

Polynucleotides that encode the Xenopus slit protein along with the deduced amino acid sequence of the Xenopus slit protein are given. Recombinant polynucleotides, vectors and transformed cells containing the slit polynucleotide are disclosed. Methods for production of slit proteins, pharmaceutical compounds containing slit protein and therapeutic uses for slit protein are also given. Methods for the repulsive guidance of nerve axon growth and inhibition of cell migration using slit are provided. Methods of stimulating cell proliferation using slit are given, along with methods and compositions for reducing the use of serum in cell culture by the use of slit.
PCT/US2000/007040 1999-03-17 2000-03-16 Vertebrate protein slit, dna sequence encoding it and uses thereof WO2000055321A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002365214A CA2365214A1 (en) 1999-03-17 2000-03-16 Vertebrate protein slit, dna sequence encoding it and uses thereof
AU37551/00A AU3755100A (en) 1999-03-17 2000-03-16 Vertebrate slit dna sequence, protein and uses thereof
EP00916449A EP1163336A2 (en) 1999-03-17 2000-03-16 Vertebrate protein slit, dna sequence encoding it and uses thereof
JP2000605739A JP2002538823A (en) 1999-03-17 2000-03-16 Vertebrate slit DNA sequences, proteins and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12476799P 1999-03-17 1999-03-17
US60/124,767 1999-03-17

Publications (3)

Publication Number Publication Date
WO2000055321A2 WO2000055321A2 (en) 2000-09-21
WO2000055321A3 true WO2000055321A3 (en) 2001-06-28
WO2000055321B1 WO2000055321B1 (en) 2001-07-19

Family

ID=22416700

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/007040 WO2000055321A2 (en) 1999-03-17 2000-03-16 Vertebrate protein slit, dna sequence encoding it and uses thereof

Country Status (5)

Country Link
EP (1) EP1163336A2 (en)
JP (1) JP2002538823A (en)
AU (1) AU3755100A (en)
CA (1) CA2365214A1 (en)
WO (1) WO2000055321A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000055195A1 (en) * 1999-03-18 2000-09-21 The Regents Of The University Of California Compositions for promoting nerve regeneration
US20110002972A1 (en) * 2007-09-14 2011-01-06 Scil Technology Gmbh Neuroendocrine factors for treatment of degenerative diseases
EP2036921A1 (en) * 2007-09-14 2009-03-18 Scil Technology GmbH Use of Slit, nephrin, ephrin or semaphorin for treatment of cartilage diseases
WO2014194402A1 (en) 2013-06-04 2014-12-11 The Hospital For Sick Children Methods and uses of slit for treating fibrosis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992010518A1 (en) * 1990-12-07 1992-06-25 Yale University Purified slit protein and sequence elements thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992010518A1 (en) * 1990-12-07 1992-06-25 Yale University Purified slit protein and sequence elements thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
AKIRA ITOH ET AL.: "Cloning and expression of three mammalian homologues of Drosophila slit suggest possible roles for Slit in the formation and maintenance of the nervous system", MOLECULAR BRAIN RESEARCH, vol. 62, 1998, pages 175 - 186, XP000937694 *
GREG P. HOLMES ET AL.: "Distinct but overlapping expression patterns of two vertebrate slit homologs implies functional roles in CNS development and organogenesis", MECHANICS OF DEVELOPMENT, vol. 79, 1998, pages 57 - 72, XP000912208 *
HUA-SHUN LI ET AL.: "Vertebrate Slit, a secreted ligand for the transmembrane protein Roundabout, is a repellent for olfactory bulb axons", CELL, vol. 96, no. 6, 19 March 1999 (1999-03-19), NA US, pages 807 - 818, XP002146822 *
J.-H. CHEN ET AL.: "Embryonic expression and extracellular secretion of Xenopus slit", NEUROSCIENCE, vol. 96, no. 1, 19 January 2000 (2000-01-19), pages 231 - 236, XP000900918 *
TADAYOSHI HAYATA ET AL.: "Molecular cloning of XNLRR-1, a Xenopus homolog of mouse neuronal Leucine-rich repeat protein expressed in the developing Xenopus nervous system", GENE, vol. 221, no. 1, October 1998 (1998-10-01), AMSTERDAM NL, pages 159 - 166, XP004143153 *

Also Published As

Publication number Publication date
CA2365214A1 (en) 2000-09-21
AU3755100A (en) 2000-10-04
EP1163336A2 (en) 2001-12-19
WO2000055321B1 (en) 2001-07-19
JP2002538823A (en) 2002-11-19
WO2000055321A2 (en) 2000-09-21

Similar Documents

Publication Publication Date Title
CA2294516A1 (en) Ikk-.beta. proteins, nucleic acids and methods
EP2277889A3 (en) Fusion proteins of albumin and interferon beta
BRPI0509278A (en) isolated polypeptide, isolated nucleic acid molecule, vector, isolated host cell, packaging cell line, biocompatibly implantable cellular device, pharmaceutical composition, use of the polypeptide, or isolated nucleic acid sequence, or expression vector, or composition of host cells, or a biocompatibly implantable cellular device or a packaging cell line, method of treating a pathological condition in an individual, methods for preventing apoptosis in a mammalian neuronal cell, to enhance the survival of a neuronal cell mammalian cells, to generate a neuron, to expand a mammalian cell composition, and to differentiate a mammalian cell composition, antibody, and, immunoconjugate
EP0796913A3 (en) GDP dissociation stimulating protein, brain-specific nucleosome assembly protein, skeletal muscle specific ubiquitin-conjugating enzyme, cell proliferation protein, phosphatidylinositolkinase, nel related proteins
DE68929043D1 (en) DNA ENCODING ANDROGEN RECEPTOR PROTEIN
IL142905A0 (en) Functional antagonists of hedgehog activity
TR199802252T2 (en) Reject ligand (RetL) for stimulation of neural and renal development
DE69738370D1 (en) MODULATORS OF THE TNF RECEPTOR ASSOCIATED FACTOR, THEIR PREPARATION AND USES
NZ279963A (en) Human tissue inhibitor of metalloproteinase-4 (timp-4) and dna (rna) encoding polypeptide which may be derived from atcc 75946
DE69808743D1 (en) Netrinrezeptoren
DE69939330D1 (en) GROWTH FACTOR HOMOLOGIST ZVEGF-3
RU2010103157A (en) Fused Growth Hormone Proteins
BR9700957A (en) Mutant human growth hormone protein deoxyribonucleotide peptide of a protein expression plasmid antibody product medications for the treatment of gigantism and acromegaly and for gene therapy
CA2281895A1 (en) Ikb kinases
EP0232523A3 (en) Dna sequences which encode for proteins with the biological activity of husi-type i inhibitors, their production by gene technology and drugs containing these proteins
CA2294566A1 (en) Ikk-.alpha. proteins, nucleic acids and methods
ATE402995T1 (en) ACT-3 NUCLEIC ACID, POLYPEPTIDES AND THEIR USE
CA2265444A1 (en) Tnf-beta-like protein for treating prostate cancer, and related nucleic acid molecules, pharmaceutical compositions and methods
WO2000055321A3 (en) Vertebrate protein slit, dna sequence encoding it and uses thereof
KR920012440A (en) Human interleukin-5 receptor
AU8811298A (en) Novel peptides and polypeptides useful for regenerating the nervous system
MXPA01011158A (en) Growth factor homolog zvegf4.
DK0977859T3 (en) The neurotrophic factor NNT-1
WO2003018804A1 (en) Proteins having effects of controlling cell migration and cell death
WO1998025957A3 (en) Human prt1-like subunit protein (hprt1) and human eif4g-like protein (p97) genes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: B1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: B1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

B Later publication of amended claims
WWE Wipo information: entry into national phase

Ref document number: 37551/00

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2365214

Country of ref document: CA

Ref country code: CA

Ref document number: 2365214

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 605739

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000916449

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000916449

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000916449

Country of ref document: EP